<DOC>
	<DOCNO>NCT01951924</DOCNO>
	<brief_summary>The aim study evaluate efficacy safety I10E ( LFB 10 % ready-to-use liquid human intravenous immunoglobulin ) compare Kiovig® maintenance treatment MMN randomize , double-blind , active comparator-controlled , cross-over trial .</brief_summary>
	<brief_title>LIME Study ( LFB IVIg MMN Efficacy Study )</brief_title>
	<detailed_description>Multifocal motor neuropathy ( MMN ) chronic acquire , probably autoimmune , demyelinate , motor neuropathy . It rare disease , variable clinical feature . The disease course usually steadily progressive . Intravenous immunoglobulin ( IVIg ) standard first line treatment MMN . The Cochrane review four randomized placebo-controlled study show significant clinical improvement muscle strength IVIg 78 % patient MMN versus 4 % placebo non-significant improvement disability ( 39 % versus 11 % ) ( van Schaik IN , 2005 ) . However , IVIg treatment prevent mild gradual decline muscle strength probably due ongoing axonal degeneration . In addition efficacy , IVIg also safe treatment positive benefit-risk ratio MMN . Muscle strength measure Modified Medical Research Council ( MMRC 10 ) sum score describe study Cats ( Cats EA , 2008 ) include 20 movement i.e . 10 muscle group upper low limbs side select primary endpoint . Other parameter muscle strength measurement grip strength dynamometer - functional disability also evaluate reinforce robustness study substantiate efficacy I10E MMN patient .</detailed_description>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<criteria>1 . Male female patient age 18 80 year . 2 . Written inform consent obtain prior studyrelated procedure . 3 . Diagnosis definite probable MMN accord EFNS/PNS Guideline 2010 , First revision make neuromuscular disease specialist specific electrodiagnostic expertise . 4 . Patients treat stable maintenance dose within 15 % brand IVIg ( Kiovig® exclude ) 1 g/kg 13 day 2 g/Kg 25 day every 4 8 week ( +/ 7 day ) , accord EFNS/PNS Guideline 2010 , First revision least 3 month prior enrolment . 5 . Covered national health care insurance system require local regulation . 1 . Upper motor neuron , bulbar , cranial nerve significant sensory deficit . 2 . CSF protein &gt; 100 mg/dL ( available do part previous evaluation ) . 3 . Any ongoing disease may cause neuropathy , toxin exposure , dietary difficency , uncontrolled diabetes , hyperthyroidism , cancer , systemic lupus erythematosus connective disease , infection HIV , hepatitis B virus ( HBV ) , hepatitis C ( HCV ) , Lyme disease , multiple myeloma , Waldenström 's macroglobulinemia , amyloid , hereditary neuropathy . 4 . BMI &gt; = 40 kg/m2 . 5 . Known hypersensitivity active substance excipients I10E ( glycine polysorbate 80 ) Kiovig ( glycine ) . 6 . Patient treat Kiovig shall receive Kiovig last 6 month prior enrolment . 7 . History IgA deficiency , except absence antiIgA antibody document . 8 . Proteinlosing enteropathy characterise serum protein level &lt; 60 g/l serum albumin level &lt; 30 g/l nephrotic syndrome characterise proteinuria &gt; =3.5 g/24 hour , serum protein level &lt; 60 g/l serum albumin level &lt; 30 g/l . 9 . History cardiac insufficiency ( New York Heart Association ( NYHA ) III/IV ) , uncontrolled cardiac arrythmia , unstable ischemic heart disease , uncontrolled hypertension . 10 . History venous thromboembolic disease , myocardial infarction , cerebrovascular accident . 11 . Risk factor blood hyperviscosity cryoglobulinemia haematological malignancy monoclonal gammopathy . 12 . Glomerular filtration rate &lt; 80 ml/min/1.73m2 measure accord Modified Diet Renal Disease ( MDRD ) calculation . 13 . Serum level AST , ALT &gt; 2 time upper limit normal range . 14 . Treatment within 12 month prior screeening immunomodulator immunosuppressant agent ( include limit cyclophosphamide , cyclosporine , interferona , interferonb 1a , antiCD20 , alemtuzumab , azathioprine , etanarcept , mycophenolate mofetil , methotrexate , haematopoietic stem cell transplantation ) . 15 . Administration another investigational product within last month prior inclusion . 16 . Plasma exchange , blood product derivative administer last 3 month prior screen . 17 . Woman positive result pregnancy test breastfeed woman woman childbearing potential without effective contraception . Effective contraception injectible , patch combine oestroprogestative progestative contraceptive , Cooper T levonorgest release intrauterine device , depot intramuscular medroxyprogesterone , subcutaneous progestative contraceptive implant , condom occlusive cap ( diaphragm cervical/vault cap ) spermicide , true abstinence ( line prefer usual lifestyle patient ) . 18 . Any serious medical condition would interfere clinical assessment I10E prevent patient comply protocol requirement . 19 . Anticipated poor compliance patient study procedure 12 month duration study . 20 . Drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Multifocal Motor Neuropathy</keyword>
</DOC>